AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1795048 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised Tomography (CT)
Number of subjects: 15
Study 1795048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CT and MR
Number of subjects: 15
Study 6134542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788
Number of subjects: 0
Study 6134542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788 with flunitrazepam
Number of subjects: 0
Study 31061043 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intramedullary nail
Number of subjects: 82
Study 31061043 — intervention group
Group type: COMPARATOR
Intervention: Anatomical locking plate
Number of subjects: 82
Study 31061043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 82
Study 29797910 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bilateral acupuncture
Number of subjects: 160
Study 29797910 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified unilateral acupuncture
Number of subjects: 160
Study 29797910 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine bilateral acupuncture
Number of subjects: 160
Study 29797910 — intervention group
Group type: COMPARATOR
Intervention: Routine unilateral acupuncture
Number of subjects: 160
Study 27467458 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 128
Study 27467458 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 128
Study 24170099 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 or 24 mg iv alemtuzumab
Number of subjects: 334
Study 24170099 — intervention group
Group type: COMPARATOR
Intervention: 44 μg sc interferon‐β‐1a (SC IFNB‐1a, Rebif)
Number of subjects: 334
Study 22297841 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist (regimen 1)
Number of subjects: 573
Study 22297841 — intervention group
Group type: COMPARATOR
Intervention: renu fresh (regimen 2)
Number of subjects: 573
Study 20652232 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alpha administration
Number of subjects: 214
Study 20652232 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin reduction only
Number of subjects: 214
Study 17650312 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission criteria based on PANSS items (scores < or = 3 for at least six months)
Number of subjects: 675
Study 17650312 — intervention group
Group type: COMPARATOR
Intervention: Total PANSS score >60
Number of subjects: 675
Study 17650312 — intervention group
Group type: COMPARATOR
Intervention: Total PANSS score <60
Number of subjects: 675
Study 16059836 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicators of Reha Status (IRES, Version 2) questionnaire
Number of subjects: 8600
Study 12145002 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g EPA/d (n = 12)
Number of subjects: 38
Study 12145002 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g DHA/d (n = 12)
Number of subjects: 38
Study 12145002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 38
Study 12145002 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA and DHA)
Number of subjects: 38
Study 9927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoneme Manipulation
Number of subjects: 0
Study 9927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Ability
Number of subjects: 0
Study 9927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal Ability
Number of subjects: 0
Study 9927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological Memory
Number of subjects: 0
Study 9927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhyme
Number of subjects: 0
Study 7564352 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 88
Study 7564352 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 88
Study 2300545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (6 g prior to phenylpropanolamine and 3 g every 4 hr for 16 hr)
Number of subjects: 4
Study 2300545 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 4
Study 7023394 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenorrhaphy
Number of subjects: 105
Study 7023394 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Group I)
Number of subjects: 105
Study 7023394 — intervention group
Group type: COMPARATOR
Intervention: Closed drainage with Jackson-Pratt drains (Group II)
Number of subjects: 105
Study 7023394 — intervention group
Group type: COMPARATOR
Intervention: Open drainage with Penrose drains (Group III)
Number of subjects: 105
Study 30785660 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 11119
Study 30785660 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 11119
Study 30785660 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 11119
Study 30785660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11119
Study 29981573 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (proparacaine eye drop)
Number of subjects: 30
Study 29981573 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 30
Study 27012727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrated with hand cooling on both hands (HY+2HC)
Number of subjects: 9
Study 27012727 — intervention group
Group type: COMPARATOR
Intervention: Hydrated with passive rest (HY)
Number of subjects: 9
Study 27012727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated with hand cooling on both hands (DY+2HC)
Number of subjects: 9
Study 27012727 — intervention group
Group type: COMPARATOR
Intervention: Dehydrated with passive rest (DY)
Number of subjects: 9
Study 25028379 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept 160 mg
Number of subjects: 1315
Study 25028379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1315
Study 22801933 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient Sprinkles alongside IYCF education
Number of subjects: 1350
Study 22801933 — intervention group
Group type: COMPARATOR
Intervention: IYCF education alone
Number of subjects: 1350
Study 20827168 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine (ABC/3TC)
Number of subjects: 357
Study 20827168 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 357
Study 17675142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/Paclitaxel
Number of subjects: 792
Study 15744511 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic thyroidectomy (MT group)
Number of subjects: 98
Study 15744511 — intervention group
Group type: COMPARATOR
Intervention: Traditional thyroidectomy (TT group)
Number of subjects: 98
Study 12154150 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) to left frontal cortex
Number of subjects: 12
Study 10503164 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforming growth factor beta (TGFb) levels in CP patients
Number of subjects: 23
Study 10503164 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum patterns of N-terminal peptide of type III procollagen (PIIIP) and laminin in CP patients
Number of subjects: 23
Study 10503164 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TGFb with PIIIP in CP patients
Number of subjects: 23
Study 10503164 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TGFb with fasting serum glucose levels in CP patients
Number of subjects: 23
Study 10503164 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of laminin with PABA test results in CP patients
Number of subjects: 23
Study 10503164 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PIIIP and laminin levels in LC patients
Number of subjects: 23
Study 10503164 — intervention group
Group type: COMPARATOR
Intervention: Inverse correlation between PIIIP and TGFb in LC patients
Number of subjects: 23
Study 8584551 — intervention group
Group type: COMPARATOR
Intervention: Supine with head of bed flat (Group 1)
Number of subjects: 69
Study 8584551 — intervention group
Group type: EXPERIMENTAL
Intervention: Side position with affected extremity straight (Group 2)
Number of subjects: 69
Study 8584551 — intervention group
Group type: EXPERIMENTAL
Intervention: Back position with head of bed at 15-30 degrees (Group 3)
Number of subjects: 69
Study 2497720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate (4.0 g omega-3 fatty acids)
Number of subjects: 18
Study 2497720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate (7.5 g omega-3 fatty acids)
Number of subjects: 18
Study 2497720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil treatment (both doses)
Number of subjects: 18
Study 2497720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil treatment (F4 dose)
Number of subjects: 18
Study 2497720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil treatment (F7.5 dose)
Number of subjects: 18
Study 2497720 — intervention group
Group type: COMPARATOR
Intervention: Safflower-oil placebo
Number of subjects: 18
Study 336174 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6-MP)
Number of subjects: 72
Study 336174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 72
Study 336174 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of 6-mercaptopurine (6-MP)
Number of subjects: 72
Study 30855202 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 80
Study 30855202 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 80
Study 29055953 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-based topical liquid 0.2%
Number of subjects: 210
Study 29055953 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil 5% solution
Number of subjects: 210
Study 25051056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pill (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Number of subjects: 118
Study 25051056 — intervention group
Group type: COMPARATOR
Intervention: ARBs except for losartan
Number of subjects: 118
Study 22889861 — intervention group
Group type: EXPERIMENTAL
Intervention: Docusate plus sennosides
Number of subjects: 74
Study 22889861 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sennosides
Number of subjects: 74
Study 21632967 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative peer feedback
Number of subjects: 185
Study 21632967 — intervention group
Group type: COMPARATOR
Intervention: Neutral peer feedback
Number of subjects: 185
Study 19710262 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate incubation of blood cultures (intervention arm)
Number of subjects: 0
Study 19710262 — intervention group
Group type: COMPARATOR
Intervention: Control (blood cultures not incubated immediately)
Number of subjects: 0
Study 16776693 — intervention group
Group type: COMPARATOR
Intervention: BoNTA 150 U
Number of subjects: 300
Study 16776693 — intervention group
Group type: COMPARATOR
Intervention: BoNTA (various doses)
Number of subjects: 300
Study 15197290 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item visual analogue format (10VAF)
Number of subjects: 3122
Study 15197290 — intervention group
Group type: COMPARATOR
Intervention: 4-item Chernoff faces
Number of subjects: 3122
Study 15197290 — intervention group
Group type: COMPARATOR
Intervention: 5-item Likert format, 5-item satisfaction format, 5-item valuation format
Number of subjects: 3122
Study 11315660 — intervention group
Group type: EXPERIMENTAL
Intervention: Input-output monitoring test with critical lures from Roediger and McDermott's paradigm
Number of subjects: 0
Study 10822119 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated study events
Number of subjects: 0
Study 10822119 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted interim analysis
Number of subjects: 0
Study 8878241 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on Day 1, followed by 5 mg/kg once daily for 4 days)
Number of subjects: 169
Study 8878241 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (40 mg/kg/day in three divided doses for 10 days)
Number of subjects: 169
Study 8878241 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 169
Study 8878241 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 169
Study 2071958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuzonam (CZON)
Number of subjects: 145
Study 2071958 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam (CTM)
Number of subjects: 145
Study 6301110 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-/radiotherapy
Number of subjects: 52
Study 6301110 — intervention group
Group type: COMPARATOR
Intervention: Radio-/chemotherapy
Number of subjects: 52
Study 6301110 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapy or combined palliative chemotherapy
Number of subjects: 52
Study 31950924 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin/10 mg solifenacin
Number of subjects: 120
Study 31950924 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mirabegron
Number of subjects: 120
Study 31950924 — intervention group
Group type: COMPARATOR
Intervention: Oral hydration for six weeks
Number of subjects: 120
Study 30328058 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin Phytosome (new formulation based on food-grade lecithin)
Number of subjects: 12
Study 30328058 — intervention group
Group type: COMPARATOR
Intervention: Unformulated quercetin
Number of subjects: 12
Study 30278517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Patch (NP)
Number of subjects: 5
Study 30278517 — intervention group
Group type: COMPARATOR
Intervention: Smoking Deprivation (SD)
Number of subjects: 5
Study 30278517 — intervention group
Group type: COMPARATOR
Intervention: Smoking (S)
Number of subjects: 5
Study 30278517 — intervention group
Group type: COMPARATOR
Intervention: Smoking Deprivation combined with Placebo Patch (SD+PP)
Number of subjects: 5
Study 30278517 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Deprivation combined with Nicotine Patch (SD+NP)
Number of subjects: 5
Study 26709597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% benvitimod cream
Number of subjects: 36
Study 26709597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% benvitimod cream
Number of subjects: 36
Study 26709597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% benvitimod cream
Number of subjects: 36
Study 26709597 — intervention group
Group type: COMPARATOR
Intervention: 0% (placebo) benvitimod cream
Number of subjects: 36
Study 24901635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 208
Study 24901635 — intervention group
Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 208
Study 21518375 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 2mg alone
Number of subjects: 10
Study 21518375 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2mg with ketoconazole 200mg
Number of subjects: 10
Study 19284399 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 95
Study 19284399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 19284399 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 95
Study 17724151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold‐adapted influenza vaccine, trivalent (CAIV‐T)
Number of subjects: 942
Study 17724151 — intervention group
Group type: COMPARATOR
Intervention: Frozen live attenuated influenza vaccine (LAIV)
Number of subjects: 942
Study 16051118 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR RV pacing > 40%
Number of subjects: 380
Study 16051118 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR RV pacing <= 40%
Number of subjects: 380
Study 16051118 — intervention group
Group type: COMPARATOR
Intervention: VVI group
Number of subjects: 380
Study 16051118 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 380
Study 12469002 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 75 mg/day)
Number of subjects: 10
Study 9855508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (0.05 to 0.65 mg/day)
Number of subjects: 16
Study 9855508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8308518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HIV-positive IVDA
Number of subjects: 552
Study 8308518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HIV-positive heterosexual contacts
Number of subjects: 552
Study 8308518 — intervention group
Group type: COMPARATOR
Intervention: At-risk groups (both anti-HIV positive and anti-HIV negative)
Number of subjects: 552
Study 8308518 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with CD4+ lymphocytes < 200/mm3
Number of subjects: 552
Study 8308518 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with AIDS-related complex (ARC)/AIDS
Number of subjects: 552
Study 8308518 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with stomatitis
Number of subjects: 552
Study 2529888 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 50 micrograms kg‐1 by mouth
Number of subjects: 33
Study 2529888 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine 6 micrograms kg‐1 i.m.
Number of subjects: 33
Study 2529888 — intervention group
Group type: COMPARATOR
Intervention: Both groups (lorazepam and hyoscine)
Number of subjects: 33
Study 30615625 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto curriculum
Number of subjects: 6391
Study 30615625 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no prevention program)
Number of subjects: 6391
Study 28464006 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal education in small classes (3 sessions during pregnancy and 1 after delivery, each lasting 2.5 hours)
Number of subjects: 1766
Study 28464006 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal education in small classes
Number of subjects: 1766
Study 28464006 — intervention group
Group type: COMPARATOR
Intervention: Standard care (2 sessions of 2 hours auditorium-based lectures)
Number of subjects: 1766
Study 25343945 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 62
Study 24622318 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg 3TW(AM)
Number of subjects: 460
Study 24622318 — intervention group
Group type: COMPARATOR
Intervention: IGlar OD
Number of subjects: 460
Study 24622318 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg 3TW(PM)
Number of subjects: 460
Study 21551424 — intervention group
Group type: EXPERIMENTAL
Intervention: Commit to Quit video, A Pregnant Woman's Guide to Quit Smoking, and counseling (experimental group)
Number of subjects: 1093
Study 21551424 — intervention group
Group type: COMPARATOR
Intervention: Brief routine advice to quit (control group)
Number of subjects: 1093
Study 21551424 — intervention group
Group type: COMPARATOR
Intervention: Historical Comparison group (Phase 1)
Number of subjects: 1093
Study 21551424 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Phase 1)
Number of subjects: 1093
Study 19697647 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient appliance therapy (T group)
Number of subjects: 48
Study 19697647 — intervention group
Group type: COMPARATOR
Intervention: Nonoccluding appliance (C group)
Number of subjects: 48
Study 16469988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (heat-treated)
Number of subjects: 20
Study 16469988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (untreated)
Number of subjects: 20
Study 16469988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (combined)
Number of subjects: 20
Study 16469988 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 20
Study 15609798 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking relapse prevention intervention
Number of subjects: 0
Study 15609798 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness of smoking cessation
Number of subjects: 0
Study 10896230 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIII-FS
Number of subjects: 71
Study 9492437 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo PGE1
Number of subjects: 0
Study 9492437 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9492437 — intervention group
Group type: COMPARATOR
Intervention: Non-effective group
Number of subjects: 0
Study 8318446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential constraint during treatment
Number of subjects: 64
Study 8318446 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative restriction during treatment
Number of subjects: 64
Study 3566358 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 24
Study 3566358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29973195 — intervention group
Group type: EXPERIMENTAL
Intervention: J. regia leaf extract (100 mg, twice daily for 8 weeks)
Number of subjects: 40
Study 29973195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose, twice daily for 8 weeks)
Number of subjects: 40
Study 28247624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenetic spermatoprotective therapy including zinc and selenium based dietary supplement and chorionic gonadotropin
Number of subjects: 72
Study 28247624 — intervention group
Group type: COMPARATOR
Intervention: Etiotropic TB therapy (control group)
Number of subjects: 72
Study 26002052 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (maximum dose 200 mg/day)
Number of subjects: 24
Study 26002052 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine (maximum dose 30 mg/kg/day)
Number of subjects: 24
Study 26002052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22955689 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL-40 levels in patients with MACE (194±104 μg/L)
Number of subjects: 80
Study 22955689 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL-40 level as a predictor for MACE
Number of subjects: 80
Study 22955689 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte count as a predictor for MACE
Number of subjects: 80
Study 22955689 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of YKL-40 to predict MACE
Number of subjects: 80